Expertise in
5
conditions

Martin Gramatzki

Kiel, SH, DE 
Expertise in
5
conditions
Kiel, SH, DE 

Overview

Martin Gramatzki practices practicing medicine in Kiel, Germany.

Mr. Gramatzki is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Plasmacytoma, Leukemia, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 72 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Kiel, SH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV
Enrollment Status: Unknown
Publish Date: April 27, 2023
Intervention Type: Biological, Drug
Study Drugs: Lenalidomide, Bortezomib, Autologous Stem Cell Transplant, Aallogeneic Stem Cell Transplant
Study Phase: Phase 3

72 Total Publications

Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.
Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.
Journal: Leukemia & lymphoma
Published: August 02, 2026

Frequently Asked Questions about Martin Gramatzki

Is Martin Gramatzki a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Martin Gramatzki is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Martin Gramatzki participate in research or clinical trials?

Yes. Martin Gramatzki has published 72 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Martin Gramatzki's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gramatzki's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile